Research progress of perioperative immunotherapy for locally advanced gastric cancer-Reference-Cited by-同舟云学术

Research progress of perioperative immunotherapy for locally advanced gastric cancer

Published:2024-02-22 Issue: Volume: Page:1-8
ISSN:2708-7999
Container-title:Asia-Pacific Journal of Oncology
language:en
Short-container-title:Asia-Pac J Oncol

Author:

Ma Shanbo¹,Wei Zhang Wei²,Xiaodi Guo Xiaodi¹,Chen Yuhan³,Zhao Zhiyong⁴,Jiang Hongbo⁵

Affiliation:

1. The College of Life Sciences, Northwest University, Xi’an City, P.R. China.

2. Department of Liver Disease, Daxing Hospital, Xi’an City, P.R. China.

3. Drug Clinical Trial Institution of The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang City, P.R. China.

4. Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen City, P.R. China.

5. Shaanxi Province Forest Industry Worker Hospital, Xi’an City, P.R. China.

Abstract

Gastric cancer is a highly heterogeneous disease, and its occurrence and development are the result of genetic factors, environmental factors, and host factors. As one of the main types of cancer in China, radical gastrectomy is the only chance for patients to be cured, but only 50% to 60% of initially diagnosed gastric cancer patients are suitable for radical gastrectomy, especially in locally advanced and advanced patients. The results of MAGIC and ACCORD07/FFCD9703 confirm the status of combination chemotherapy with fluorouracil as the standard of perioperative treatment for locally advanced gastric cancer. Gastric cancer is one of the most common diseases in China, with high heterogeneity and poor prognosis. Immunotherapy has always been a difficulty in medical research. However, the 5-year overall survival rate for gastric cancer patients remains low. Immunotherapy is effective in the first-line treatment of advanced gastric cancer. At the same time, immunotherapies such as immune checkpoint inhibitors, tumor vaccines, and cell therapy also show certain safety and effectiveness in the perioperative treatment of locally advanced gastric cancer patients. This paper reviews the research progress of immunotherapy in the perioperative treatment of locally advanced gastric cancer.

Publisher

Asian Medical Press Limited

Reference62 articles.

1. Sung H, Ferlay J, Siegel RL: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021, 71(3): 209-249.

2. Siegel RL, Miller KD: Cancer Statistics, 2021. CA Cancer J Clin 2021, 71(1):7-33.

3. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F: Gastric cancer. Lancet 2020, 396(10251): 635-648.

4. Zheng RS, Zhang SW, Sun KX, Chen R, Wang SM, Li L, Zeng HM, Wei WW, He J: [Cancer statistics in China, 2016]. Zhonghua Zhong Liu Za Zhi 2023, 45(3): 212-220.

5. Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, et al: Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomized, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2021, 6(12): 1015-1024.